A review of phototherapy protocols for psoriasis treatment - 10/08/11
Reprint requests: Steven R. Feldman, MD, PhD, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1071.Abstract |
Phototherapy is a mainstay in the treatment of psoriasis and is available as psoralen plus UVA (PUVA), broadband UVB (BB-UVB), and narrowband UVB (NB-UVB). Phototherapy can be administered in the hospital, outpatient clinic, or in the patient's home. The purpose of this review is to provide some practical guidance to general dermatologists and residents on the specifics of using phototherapy, which, despite its decreasing use, remains one of our most safe and effective treatment strategies for psoriasis care. We conducted a literature review of home phototherapy, BB-UVB, NB-UVB, and PUVA phototherapy using PubMed, MD Consult, and reference lists. A variety of protocols for BB-UVB, NB-UVB, and PUVA have been used in clinical trials. NB-UVB is more effective than BB-UVB and safer than PUVA. Typical regimens for NB-UVB involve dosing 3 times per week for at least 3 months. Treatment must be independently developed to suit each participant's needs. Ultraviolet light is an effective, relatively safe modality that is a valuable tool in the treatment of psoriasis. NB-UVB phototherapy is considered the first-line treatment for extensive plaque type psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : excimer, light, monochromatic, narrowband, NB-UVB, psoralen, psoriasis, PUVA, targeted, ultraviolet, UVA, UVB
Abbreviations used : BB-UVB, CR, MED, MEL, 8-MOP, MPD, NB-UVB, PASI, PUVA, RePUVA, TMP
Plan
| The Center for Dermatology Research is supported in part by unrestricted educational grants from Galderma Laboratories, L.P. and National Biological Corporation. |
|
| Disclosure: Dr Feldman has received research, speaking and/or consulting support from Connetics, Roche, Amgen, Biogen, and Genentech. Dr Bagel has received research, speaking and/or consulting support from Amgen, Abbott, Centacor, Neostrata, Galderma, Warner-Chilcott, and is the owner of the Psoriasis Treatment Center of Central New Jersey. None of the other authors declared any conflicts of interest. |
Vol 64 - N° 5
P. 936-949 - mai 2011 Retour au numéro
Article précédent
- Atypical Spitzoid melanocytic tumors: A morphological, mutational, and FISH analysis
- Daniela Massi, Anna Maria Cesinaro, Carlo Tomasini, Milena Paglierani, Stefania Bettelli, Luigino Dal Maso, Lisa Simi, Francesca Salvianti, Pamela Pinzani, Claudio Orlando, Vincenzo De Giorgi, Silvana Lukic, Antonio Maiorana, Marco Santucci, Vincenzo Canzonieri
- Clinical features of pyoderma gangrenosum and current diagnostic trends
- Ahmed Hadi, Mark Lebwohl
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?